MaxCyte Inc - Ordinary Shares - Reg S MXCL
This security is delisted
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of MaxCyte Inc - Ordinary Shares - Reg S shares you hold and we'll calculate your dividend payments:
Sign up for MaxCyte Inc - Ordinary Shares - Reg S and we'll email you the dividend information when they declare.
Add MaxCyte Inc - Ordinary Shares - Reg S to receive free notifications when they declare their dividends.
Your account is set up to receive MaxCyte Inc - Ordinary Shares - Reg S notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no MaxCyte Inc - Ordinary Shares - Reg S dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0p | — |
| 2007 | 0.0p | 0% |
| 2008 | 0.0p | 0% |
| 2009 | 0.0p | 0% |
| 2010 | 0.0p | 0% |
| 2011 | 0.0p | 0% |
| 2012 | 0.0p | 0% |
| 2013 | 0.0p | 0% |
| 2014 | 0.0p | 0% |
| 2015 | 0.0p | 0% |
| 2016 | 0.0p | 0% |
| 2017 | 0.0p | 0% |
| 2018 | 0.0p | 0% |
| 2019 | 0.0p | 0% |
| 2020 | 0.0p | 0% |
| 2021 | 0.0p | 0% |
| 2022 | 0.0p | 0% |
| 2023 | 0.0p | 0% |
| 2024 | 0.0p | 0% |
| 2025 | Sign Up Required | |
MaxCyte Inc Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on
- 52 Week Low
- 0.0% on
- Next Ex-Div-Date Countdown
- Sign Up Required
About MaxCyte Inc
MaxCyte, Inc. (MaxCyte) is a life sciences company. The Company is focused on advancing the discovery, development and commercialization of cell therapies. The Company provide cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. MaxCyte has developed and commercialized Flow Electroporation platform, which facilitates engineering of a wide variety of cells. The Company's ExPERT platform, which is based on Flow Electroporation technology, is designed to address the expanding cell therapy market, and used across the continuum of the cell therapy sector. The ExPERT family of products includes: three instruments, the ATx, STx and GTx. MaxCyte has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- United Kingdom
- Share Price
- £9.25 (closing price on 14 Nov 2021)
- Shares in Issue
- 10 million
- Market Cap
- £92mn
- 0
- Market Indices
- none
- Other listings
- London Stock Exchange
